@prefix bl: .
@prefix nkg: .
@prefix nt: .
@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo;
a np:Nanopublication .
}
sub:assertion {
a bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001).";
bl:has_population_context sub:context;
bl:provided_by ;
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:context a bl:Cohort;
rdfs:label "Adults" .
a bl:Drug .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-08-16T20:58:19.629539"^^xsd:dateTime .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "dQLrGebw1x7RtUmh3dbS4NpT5gUdN48SmRVQNHc64d2GTsTILdtkPFOcjoEAk6hJjcVSxD5EJFhU8ob96i+QihxDyIezY0GfdjPwsCP3IJWClQ9pvIFVD80uI/lqc8HmbxfdL+SHph3VrxG8pkC+l1tPNux0iSKoqfUXYOg0hy4=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-08-16T20:58:19.629539"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-7641-6446;
nt:wasCreatedFromTemplate .
}